medications – Page 32 – Communicable Diseases Research

Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort

Research Article

Published on 2020-08-202022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS, SARS,

Drug treatments affecting ACE2 in COVID-19 infection: a systematic review protocol

COVID-19 감염에서 ACE2에 영향을 미치는 약물 치료: 체계적인 검토 프로토콜

Research

Published on 2020-08-152022-09-10
Journal: BJGP Open [Category] 비임상,

[키워드] ACE2 ACE2 expression Affect affecting angiotensin angiotensin-converting enzyme 2 bind breath British National Formulary center children CINAHL Cochrane Library comparator conducted COVID-19 COVID-19 infection COVID-19 transmission criteria Critical decrease down-regulate drug drug therapies drug treatment drug treatments enzyme Evidence exclusion criteria expression human Angiotensin-converting enzyme human tissues identify in utero inception inclusion criteria index Infection Intervention item Laboratory animal literature medication medications mortality rates National Formulary Nursing Placebo Primary Health Care PRISMA promote protocol Quality receptor reduce reported Reporting Research Result review risk of bia risk of COVID-19 SARS-CoV-2 SARS-CoV-2 virus susceptible systematic review target targets therapy Transmission Web of Science with COVID-19
[DOI] 10.3399/bjgpopen20X101115 PMC 바로가기 [Article Type] Research

COVID-19 Usurps Host Regulatory Networks

Pharmacology

Published on 2020-08-142022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] ACE2 Activation acute respiratory syndrome Angiotensin II angiotensin-converting enzyme 2 Anti-viral therapy benefit bind bradykinin cause Cell Central nervous system characteristic Coagulation coagulation cascade complement complex Coronary heart disease coronavirus coronavirus disease COVID-19 deficiencies diabetes Effect effective hypertension identify immune Infection inflammatory signal inhibitor Intervention Kallikrein-kinin system Kidney disease lack manifestation medications network organ pathophysiological pathway Pathways Patient pharmacotherapy physiological pro-inflammatory condition prothrombotic RAAS renin-angiotensin-aldosterone system SARS-CoV-2 SARS-COV-2 infection substance P susceptible Symptom tissue damage Treatment underlying disease understanding while
[DOI] 10.3389/fphar.2020.01278 PMC 바로가기 [Article Type] Pharmacology

Development and validation of a model for individualized prediction of hospitalization risk in 4,536 patients with COVID-19

Research Article

Published on 2020-08-112022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS, SARS,

[키워드] 95% CI 95% confidence interval Algorithm calculator calibration co-morbidities Cohort cohort study collected complex COVID-19 progression demographic develop development diabetes diagnosed with COVID-19 diarrhea discharged home Disease progression facilitate feature Final flu vaccination Health healthcare Healthcare system hospital Hospitalization hypertension Immunosuppressive treatment infected with SARS-CoV-2 Influenza intensive care Laboratory large cohort limitation Logistic regression Lung disease Male sex measurement medication medications Model Multiple NSAIDS objective Older age operator outcome outcomes pandemic participant Patient patient cohort patients patients died patients hospitalized patients with COVID-19 positive Predictive presenting symptoms provide required resources Result risk risk factor SARS-CoV-2 scaled setting Shortness of breath smoking statistical model study period tested transferred vaccination validation cohort was increased was reduced with COVID-19
[DOI] 10.1371/journal.pone.0237419 PMC 바로가기 [Article Type] Research Article

Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies

Review Article

Published on 2020-08-102022-10-29
Journal: Pulmonary Medicine [Category] COVID-19, MERS, SARS,

Comorbidity Assessment Is Essential During COVID-19 Treatment

Physiology

Published on 2020-08-042022-10-31
Journal: Frontiers in Physiology [Category] COVID-19,

[키워드] ACE inhibitors affected Analysis assessment blockers cardiovascular disease cardiovascular diseases caused Comorbidities Comorbidity Coronavirus disease 2019 country COVID-19 death Deceased Deterioration determine diabete diabetes drug dysfunction endothelial Endothelium Essential European FIVE France Healthcare system heart disease hospital Hospitalized hospitalized patient hypertension immunodeficiency individuals Italy Kidney disease liver Liver disease losartan Lung diseases majority medications modulate Mortality Netherlands neurological outcome Patient proportion retrieved SARS-CoV2 severity significantly higher Spain t -test the disease Treatment with COVID-19
[DOI] 10.3389/fphys.2020.00984 PMC 바로가기 [Article Type] Physiology

Emerging pharmacotherapies for COVID-19

Review article

Published on 2020-08-012022-10-05
Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] SARS, 신약개발,

A Panel of Broad-Spectrum Antivirals in Topical Ophthalmic Medications from the Drug Repurposing Approach during and after the Coronavirus Disease 2019 Era

Review

Published on 2020-07-302022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

[키워드] acute respiratory syndrome Antibiotics Antiviral antiviral action Antiviral treatment approach Asymptomatic caused characterized clinical manifestation coronavirus coronavirus disease Coronavirus disease 2019 (COVID-19) courses COVID-19 described drug Effect explain eye drop eye drops General population heterogeneous group hospitalized patient indicate ingredient investigated medication medications Ocular surface ophthalmic Panel patients with COVID-19 Prevalence public health reported repurposing SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Side effect Symptom therapy topical Treatment Treatment protocol viral infection viruses widespread
[DOI] 10.3390/jcm9082441 PMC 바로가기 [Article Type] Review

COVID-19 and Liver Injury: A Systematic Review and Meta-Analysis

Internal Medicine

Published on 2020-07-272022-10-31
Journal: Cureus [Category] COVID-19,

[키워드] 95% CIs 95% confidence interval ALT Analysis articles AST baseline Bilirubin caused chi-square test chronic liver disease CIs CLD Cohort conducted coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 patients database defined disease duplicate Epidemiological study estimate expected greater hepatic injury hospitalized COVID-19 patients inclusion criteria Injury limit liver abnormalities Liver damage liver enzyme liver enzymes Liver injury liver injury biomarkers material mean difference medications Meta-analysis Patient patients Prevalence proportion random-effects model required Result review SARS-CoV-2 searched severe COVID-19 severity severity of COVID-19 significantly significantly higher significantly lower standard error tested the disease transaminase virus was used with COVID-19
[DOI] 10.7759/cureus.9424 PMC 바로가기 [Article Type] Internal Medicine

Renin-Angiotensin-Aldosterone System Blockers Are Not Associated With Coronavirus Disease 2019 (COVID-19) Hospitalization: Study of 1,439 UK Biobank Cases

Cardiovascular Medicine

Published on 2020-07-142022-10-31
Journal: Frontiers in Cardiovascular Medicine [Category] COVID-19,

[키워드] ACEi/ARB adjusted adverse outcome age angiotensin Angiotensin converting enzyme inhibitors Angiotensin receptor blockers ARBs Asian association associations Bame black blocker BMI body mass index cardiometabolic cardiometabolic disease Cohort comparison coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 negative diabetes Enzyme inhibitor Ethnicity Factor greater hospital Hospitalization hypertension increased risk individual Male sex medications moderate morbidity Myocardial infarction obesity Other participant positive positive result Regression model severe symptom Sex smoking specificity System tested UK biobank were used with COVID-19
[DOI] 10.3389/fcvm.2020.00138 PMC 바로가기 [Article Type] Cardiovascular Medicine